CAMBRIDGE, ON, Sept. 14, 2020 /CNW/ - ATS Automation Tooling
Systems Inc. (TSX: ATA) ("ATS" or the "Company"), an
industry-leading automation solutions provider, today announced it
has received a $20 million Order
Booking from a medical device manufacturer to design, build, and
deliver several automated safety syringe manufacturing systems that
will feature the Company's new, high-performance
SymphoniTM technology. The program will be
completed over the next 10 months and will enable the production of
safety syringes to meet potential demand related to COVID-19
vaccine production.
"Our teams remain focused on helping manufacturers address the
critical need for medical equipment brought on by the COVID-19
pandemic," said Andrew Hider, Chief
Executive Officer of ATS. "ATS' involvement in this critical
program highlights our significant capabilities in life sciences
and our ability to quickly enable manufacturers to scale production
at the highest levels of quality demanded in the medical device
industry through advanced technologies including Symphoni, our
latest innovation."
This program is related to the US Government's Operation Warp
Speed which seeks to increase the ability to produce safety needles
and syringes in the United States.
This effort is critical to meet anticipated demand as existing
supplies are consumed in routine healthcare and to treat the surge
of COVID-19 patients. ATS' Symphoni technology is ideal for
urgent, time-sensitive programs such as Operation Warp Speed
because its standardized, modular construction lends itself to
rapid deployment and scalable replication.
Symphoni
ATS' patented Symphoni technology will figure
prominently in these syringe manufacturing systems. Symphoni is an
innovative, high-performance digital manufacturing technology that
multiplies the productivity of automated assembly processes by
eliminating non-value-added production time. The high degree of
standardization, modular building blocks and plug-and-play nature
means Symphoni systems are versatile, multi-purpose production
assets, having the flexibility to adapt to new products and new
processes throughout their useful life. Because a Symphoni
system is digital and 100% programmable, all movements are
precisely mapped out and synchronized through a technique known as
electronic gearing resulting in a "symphony of motion". Symphoni's
disruptive combination of high-speed, high-precision, and
configurable flexibility heralds a revolution in automated
assembly. It perfectly meets the manufacturing demands of
high-volume consumables such as syringes because it assembles them
at very high rates in a compact footprint while assuring compliance
to the medical device industry's rigid quality standards.
About ATS
ATS is an industry-leading automation
solutions provider to many of the world's most successful
companies. ATS uses its extensive knowledge base and global
capabilities in custom automation, repeat automation, automation
products and value-added services, including pre-automation and
aftersales services, to address the sophisticated manufacturing
automation systems and service needs of multinational customers in
markets such as life sciences, chemicals, consumer products,
electronics, food, beverage, transportation, energy, and oil and
gas. Founded in 1978, ATS employs approximately 4,400 people at 22
manufacturing facilities and over 50 offices in North America, Europe, Southeast
Asia and China. The
Company's shares are traded on the Toronto Stock Exchange under the
symbol ATA. Visit the Company's website at
www.atsautomation.com.
Note to Readers: Forward-Looking Statements
This news
release contains certain statements that constitute forward-looking
information within the meaning of applicable securities laws
("forward-looking statements"). Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of
ATS, or developments in ATS' business or in its industry, to differ
materially from the anticipated results, performance, achievements
or developments expressed or implied by such forward-looking
statements. Forward-looking statements include all disclosure
regarding possible events, conditions or results of operations that
are based on assumptions about future economic conditions and
courses of action. Forward-looking statements may also include,
without limitation, any statement relating to future events,
conditions or circumstances. Forward-looking statements
relate to, among other things, the announcement of a new Order
Booking; the anticipated timeline for completion; and Company's new
SymphoniTM technology. The risks and uncertainties
that may affect forward-looking statements include, among others:
the progression of COVID-19 and its impacts on the Company's
ability to operate its assets, including the possible shut-down of
facilities due to COVID-19 outbreaks; the severity and duration of
the COVID-19 pandemic in all jurisdictions where the Company
conducts its business; the nature and extent of government imposed
restrictions on travel and business activities and the nature,
extent, and applicability of government assistance programs, in
both cases related to the COVID-19 pandemic, as applicable in all
jurisdictions where the Company conducts its business; the impact
of the COVID-19 pandemic on the Company's employees, customers, and
suppliers; the impact of the global economy and general market
performance; that the timing of completion of the program is other
than as expected due to various reasons, including schedule changes
or COVID-19 pandemic related factors; the customer exercising any
right to terminate the program in whole or in part prior to its
completion, thereby preventing ATS from realizing on the full
benefit of the program; that the Company's new technology does not
achieve wide-spread market acceptance or otherwise performs other
than as expected; management effectiveness and disaster response
preparedness, including business continuity plans in response to
COVID-19; that one or more customers, or other entities with which
the Company has contracted, experience insolvency or bankruptcy
with resulting delays, costs or losses to the Company; political,
labour or supplier disruptions; risks relating to legal proceedings
to which ATS is or may become a party; exposure to product and/or
professional liability claims; and other risks detailed from time
to time in ATS' filings with Canadian provincial securities
regulators. There can be no assurance that forward-looking
statements or information will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, you should not place
undue reliance on the forward-looking statements or information
contained herein which speak only as of the date they are made.
Forward-looking statements are based on management's current plans,
estimates, projections, beliefs and opinions, and other than as
required by applicable securities laws, ATS does not undertake any
obligation to update forward-looking statements should assumptions
related to these plans, estimates, projections, beliefs and
opinions change.
SOURCE ATS Automation Tooling Systems Inc.